Alpha interferon in the treatment of chronic myeloid leukaemia
Record ID 31998008870
To evaluate the efficacy of alpha interferon in the treatment of chronic myeloid leukaemia (CML).
Authors' results and conclusions: Both studies confirmed that the survival of patients in the IFN treatment arm was significantly longer than for patients in the conventional chemotherapy arm. In both studies survival was significantly linked to the haematological and cytogenetic response. The authors conclude that continued administration of IFN, even when there is a poor haematological response, appears to confer some benefit in terms of survival.
Authors' recommendations: IFN-alpha treatment is strongly recommended, though at a low dose. The author further recommends that physicians should be encouraged to enter eligible CML patients into the CML V trial, which will determine the optimum dosage level. Other treatments which are cheaper than IFN have positive benefits, but these are rather less than with IFN.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Antineoplastic Agents
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.